Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$9.54
▲ $0.16 (+1.7%)
Market data updated: 09/20 07:31 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$1.90B
Day Range
$9.37 - $9.64
52-Week Range
$9.36 - $14.76
Beta
—
Next Earnings
04.11.2026
Support
$9.36
Resistance
$14.44
XRAY is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-28.9% (1Y)
Strengths: 6/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Golden Cross
SMA 50 recently crossed above SMA 200
Technical
Biggest negative driver
Operating margin
Operating margin: -11.5% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
60
Quality
42
Value
50
Momentum
17
Risk
34
Sentiment
86
Fundamental
31
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **DENTSPLY SIRONA Inc.** (XRAY) has centered on its **return to profitability in Q2 2026**, despite a **4.1% year-over-year decline in net sales**, alongside improved margins and stronger cash flow. Analysts highlight **mixed investor sentiment**, with the stock trading at a discount amid a **79.6% drop over five years**, though the company reaffirmed its 2026 guidance. The firm is also preparing to present at the **Baird 2026 Global Healthcare Conference** on September 15, 2026, as it navigates ongoing market uncertainty.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about DENTSPLY SIRONA Inc.. News trend score: 86. Reason: 10 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
32
🎯 Conviction (vs. Emotion)
36
Psychology
62
Fundamentals
31
Technical
17
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Price (3M)
-8%
Market Narrative
47
Fundamental Reality
36
Narrative Gap
+11
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for XRAY suggests a dominant **Confirmation Bias** and **Anchoring**, where investors cling to a positive narrative despite weak revenue growth and marginal margin gains. The narrative gap (+27) and proximity to support (3.5%) imply traders are prioritizing price action over fundamentals, potentially delaying critical reassessment. Overconfidence in price momentum (+1.9%) over EPS growth (+0.3%) further reinforces selective justification. The key open question is whether the stock’s underperformance relative to peers will force a reevaluation of its anchoring point or if traders remain anchored to the narrative despite stagnant fundamentals.
Updated: 09/09/2026, 09:42 AM
What could change this?
👥 What the crowd believes
"swung from a $45 million net loss a year earlier to $37 million in net income"
"held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery"
"shareholders have seen the stock fall about 79.6% over the past 5 years"
"Management is scheduled to present on Tuesday, September 15, 2026, at the Baird 2026 Global Healthcare Conference"
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The methodologies for XRAY split sharply between bullish and bearish camps, reflecting starkly different priorities. Samuel Armstrong Nelson and Charles Mackay’s high scores (79 and 75) suggest a favorable cycle position and absence of crowd-driven mania, while Jack Schwager’s disciplined, reward/risk-focused approach also leans positive. However, the majority of investors—from Peter Lynch and Benjamin Graham to Morgan Housel—flag concerns: Lynch and Graham see the stock as overpriced relative to its growth, while Housel and Loeb warn of excessive volatility and risk. The divide highlights whether one prioritizes technical or cyclical tailwinds (Nelson, Mackay) versus fundamental valuation or risk tolerance (Graham, Housel), with Fisher’s near-zero score underscoring a complete lack of the quality/growth traits he demanded.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 81
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 78
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 66
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 65
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 53
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 45
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 42
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 42
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 34
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 33
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 24
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 20
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 20
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 9
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
50.0%
Operating Margin
-11.5%
Net Margin
-16.3%
EBITDA Margin
-1.9%
ROE
-44.7%
ROA
-11.0%
ROIC
—
EPS
-$3.00
Cash
$326.00M
Total Debt
$2.24B
Current Ratio
1.51
Debt/Equity
1.68
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 26.12.2025 | $0.160 |
| 25.12.2025 | $0.160 |
| 26.9.2025 | $0.160 |
| 25.9.2025 | $0.160 |
| 27.6.2025 | $0.160 |
| 26.6.2025 | $0.160 |
| 28.3.2025 | $0.160 |
| 27.3.2025 | $0.160 |
| 27.12.2024 | $0.160 |
| 26.12.2024 | $0.160 |
| 27.9.2024 | $0.160 |
| 26.9.2024 | $0.160 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$6.72
Tangible Book Value per Share (Tangible NAV)
-$3.93
Sentiment based on basic keywords (not AI) — 10 positive, 6 neutral, 4 negative out of the last 20 articles.
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 11.9.2026
StockStory · 11.9.2026
Zacks · 8.9.2026
Yahoo · 8.9.2026
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
GlobeNewswire · 3.9.2026
Yahoo · 3.9.2026
Yahoo · 3.9.2026
Insider Monkey · 3.9.2026
Yahoo · 3.9.2026
StockStory · 3.9.2026
Yahoo · 24.8.2026
StockStory · 24.8.2026
DENTSPLY SIRONA Inc. (XRAY) currently has a StockIQ AI score of 41/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
XRAY currently scores 41/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
XRAY's technical score is 17/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: SMA 50 recently crossed above SMA 200; Earnings per share (EPS) growth: 33.0%; Net income growth: 34.3%.
Based on the real signals StockIQ computed: Operating margin: -11.5% (negative); Net margin: -16.3% (negative); Operating margin is eroding over time.
Yes — XRAY has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 10 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Fortson John C. | Grant/Award from Employer | 10.8.2026 | 104,200 | +104,200 | — |
| Fortson John C. | Grant/Award from Employer | 10.8.2026 | 24,014 | +24,014 | — |
| Fortson John C. | Grant/Award from Employer | 10.8.2026 | 24,014 | +24,014 | — |
| Fortson John C. | Grant/Award from Employer | 10.8.2026 | 104,200 | +104,200 | — |
| Frohning Andrea L. | Tax Withholding in Shares | 7.8.2026 | 802 | -802 | $12.12 |
| Frohning Andrea L. | Tax Withholding in Shares | 7.8.2026 | 63,191 | -802 | $12.12 |
| MAZELSKY JONATHAN JAY | Grant/Award from Employer | 30.6.2026 | 2,841.83 | +2,841.83 | $10.56 |
| MAZELSKY JONATHAN JAY | Grant/Award from Employer | 30.6.2026 | 20,022 | +2,842 | $10.56 |
| Gladden Brian T | Open Market Purchase | 15.6.2026 | 9,985.022 | +9,985.022 | $10.02 |
| HOSEIN CLYDE | Open Market Purchase | 15.6.2026 | 6,500 | +6,500 | $9.99 |
| Gladden Brian T | Open Market Purchase | 15.6.2026 | 61,849 | +9,985 | $10.02 |
| HOSEIN CLYDE | Open Market Purchase | 15.6.2026 | 70,575 | +6,500 | $9.99 |
| MAZELSKY JONATHAN JAY | Grant/Award from Employer | 12.6.2026 | 10,000 | +10,000 | $10.14 |
| MCKEON BRIAN P | Open Market Purchase | 12.6.2026 | 10,000 | +10,000 | $10.12 |
| MCKEON BRIAN P | Open Market Purchase | 12.6.2026 | 10,000 | +10,000 | $10.12 |
| MAZELSKY JONATHAN JAY | Grant/Award from Employer | 12.6.2026 | 61,669 | +10,000 | $10.14 |
| Barber Michael J | Open Market Purchase | 11.6.2026 | 15,175 | +15,175 | $9.89 |
| HOLDEN BETSY D | Open Market Purchase | 11.6.2026 | 10,086 | +10,086 | $9.88 |
| HOLDEN BETSY D | Open Market Purchase | 11.6.2026 | 87,528 | +10,086 | $9.88 |
| Barber Michael J | Open Market Purchase | 11.6.2026 | 55,943 | +15,175 | $9.89 |
| MCKEON BRIAN P | Grant/Award from Employer | 3.6.2026 | 28,887 | +28,887 | — |
| MAZELSKY JONATHAN JAY | Grant/Award from Employer | 3.6.2026 | 22,822 | +22,822 | — |
| VARON LESLIE F | Grant/Award from Employer | 3.6.2026 | 22,822 | +22,822 | — |
| Vergis Janet S. | Grant/Award from Employer | 3.6.2026 | 22,822 | +22,822 | — |
| Zurbay Donald | Grant/Award from Employer | 3.6.2026 | 22,822 | +22,822 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
22,085,831 shares short as of 2026-08-31 · vs. 23,604,124 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
64.3% of trading volume this week was short selling, vs. 69.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology